
CELLmeric
One Stop Solution
for Safe and Effective Cell Therapy
Our platform avoids viruses entirely, removing risk of cancer-causing mutations due to random gene insertion. This gives our CAR-T cells a much safer profile than traditional viral approaches.
Without viral vectors or special safety labs, our system cuts production costs and speeds up manufacturing dramatically. This makes CAR-T more scalable and affordable (from >HK$1M down to <HK$0.5M per dose).
Our gene-editing efficiency is matching or even surpassing viral methods, and highly outperform other non-viral approaches. This means we could get strong CAR expression on the T-cells, which is critical for effectively targeting and killing cancer cells.
Our mission is to transform the way cancer and immune diseases are treated by making advanced cell therapies safer, more effective, and more accessible to all who need them. We are driven by the vision of a world where innovations like virus-free CAR-T cells can cure cancers that were once considered incurable, with minimal side effects and at a cost that healthcare systems can afford. This means not only creating a new therapy, but changing the paradigm of treatment – we aim to enable more patients worldwide to benefit from CAR-T cures by overcoming the current safety and cost barriers in manufacturing.
Unit 501, 5/F, Belgian Bank Building, 721-725 Nathan Road, Mongkok
email: info@cellmeric.com
CELLmeric Limited
Copyright © 2025 CELLmeric — 保留所有權利。